Substance Use, Medications & the ME's Prescription Review

Schedule I Drugs — 391.41(b)(12)

391.41(b)(12) disqualifies a driver who uses any drug or substance identified in 21 CFR 1308.11 (Schedule I), an amphetamine, a narcotic, or other habit-forming drug — with a narrow exception for a legally prescribed medication that is not a Schedule I substance, where the ME determines, after consulting the prescribing clinician, that it will not adversely affect safe operation.

Marijuana Stays Disqualifying, Regardless of State Law

Marijuana, including extracts above 0.3% THC, remains a federal Schedule I substance. Use disqualifies a driver under 391.41(b)(12) even in states where marijuana is legal for recreational or medical use; state legalization has no bearing on the federal physical-qualification standard. CBD products containing less than 0.3% THC are not Schedule I substances, so their use is not automatic grounds for disqualification, though the ME should still counsel drivers that mislabeled CBD products can carry enough THC to trigger a positive drug test, an operational risk distinct from the certification standard itself.

Alcoholism — 391.41(b)(13)

391.41(b)(13) disqualifies a driver with a current clinical diagnosis of alcoholism. The word "current" matters: a documented history of alcohol use disorder that is in sustained remission, with treatment and monitoring, is evaluated differently from an active diagnosis — the ME weighs the specific clinical picture rather than treating any past diagnosis as a permanent bar.

Methadone and Medication-Assisted Treatment: A Judgment Call, Not an Automatic Bar

Older guidance once treated methadone as automatically disqualifying; current FMCSA guidance does not list methadone in the regulation as precluding certification. The same is true of buprenorphine/naloxone combination products such as Suboxone. Neither is a bright-line CFR bar the way marijuana use is. Instead, the ME evaluates the treatment case-by-case: obtaining the opinion of the prescribing clinician, who knows the driver's history and the specifics of the regimen, on whether the medication-assisted treatment will adversely affect the driver's ability to operate a CMV safely. In practice, many examiners remain cautious about certifying drivers on methadone maintenance because of sedation and cognitive-effect concerns, but that caution reflects individualized clinical judgment, not an automatic regulatory disqualification.

SAP Evaluation and the Return-to-Duty Process

A driver who has a DOT drug-and-alcohol testing program violation cannot return to safety-sensitive duty on the ME's certification alone. Federal rule (49 CFR Part 40) requires completion of a Substance Abuse Professional (SAP) evaluation and a documented return-to-duty process before the driver resumes CMV operation. The SAP evaluates the driver, recommends education or treatment, confirms compliance, and only then may the driver take a negative return-to-duty test followed by a follow-up testing plan set by the SAP. The ME reviews SAP results and return-to-duty status as part of the driver's documented history — the same ancillary-documentation discipline covered under the Medical Examination Report — but the ME does not conduct the SAP evaluation itself; that is a distinct, specialized role under Part 40.

The ME's General Medication-Review Role

At every DOT physical, the ME reviews all prescription, over-the-counter, and supplement use the driver reports on the health history, not just the substances named in (b)(12) and (b)(13). Medication classes that routinely draw closer scrutiny include:

• Opioid analgesics — sedation, slowed reaction time, and, if habit-forming without a valid ongoing prescription, potential (b)(12) exposure
• Benzodiazepines and other sedative-hypnotics — sedation and next-day impairment even with therapeutic dosing
• Sedating antihistamines and sleep aids — often OTC, and easy for a driver to under-report as "not a real medication"
• Stimulants (ADHD treatment, some weight-loss agents) — reviewed under the same legally-prescribed, non-Schedule-I framework discussed for ADHD in the psychiatric standard
• Anticoagulants and antiplatelet agents — not sedating, but relevant to injury and bleeding risk in the event of a crash, and worth noting for the health-education counseling covered later in this guide

The task in each case is the same: identify anything sedating, cognitively impairing, or otherwise incompatible with safe CMV operation; consult the prescriber rather than disqualifying on the medication name alone; and counsel the driver to report any new medication before the next exam. This ongoing medication surveillance is one of the clearest places where the ME's exam-room judgment, rather than a fixed number, determines the outcome.

The underlying theme across 391.41(b)(12) and (b)(13) is the same distinction that runs through this entire chapter: a small number of standards (Schedule I use, a current alcoholism diagnosis) are bright-line and automatic, while most of the surrounding medication and substance questions are resolved through the ME's individualized clinical judgment, informed by the prescribing clinician, rather than a fixed rule that can be looked up and applied mechanically.